RT Journal Article
SR Electronic
T1 SARS-CoV-2 infections in people with PCD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA917
DO 10.1183/13993003.congress-2021.PA917
VO 58
IS suppl 65
A1 Eva Sophie Lunde Pedersen
A1 Myrofora Goutaki
A1 Amanda Harris
A1 Lucy Dixon
A1 Michele Manion
A1 Bernhard Rindlisbacher
A1 Jane S Lucas
A1 Claudia E Kuehni
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA917.abstract
AB Background: People with chronic health conditions are reportedly at high risk of coronavirus disease (COVID-19) with a severe disease course. We studied risk and severity of SARS-CoV-2 infections among people with primary ciliary dyskinesia (PCD) using data from the COVID-PCD, a participatory study that collects data via online questionnaires in real-time.Methods: The COVID-PCD study includes persons of any age from anywhere in the world with a suspected or confirmed diagnosis of PCD. We collected information on demographic data, PCD diagnosis, and disease severity using a baseline questionnaire at recruitment. We collected information about current symptoms and incident SARS-CoV-2 infections via short weekly questionnaires.Results: 625 people participated in the COVID-PCD between April 31 and January 25, 2020 (median age 27 years; 61% female). Median follow-up was 12 weeks (range 1-32). 307 participants (49%) had been tested for SARS-CoV-2 and 20 tested positive (3.2%, 95% CI: 2.0-4.9%). 6 people tested positive during the study follow-up corresponding to an incidence rate of 2.9 per 100 person-years (95% CI: 1.3-6.3). Overall, reported severity was mild. 4 were asymptomatic, 9 reported mild symptoms, 4 moderate symptoms without hospitalisation, and 3 were hospitalised (1 with mild symptoms, 2 with moderate symptoms; longest hospitals stay was 9 days). Many shielded and kept social distance; on average 10% of the participants did not leave the house during a normal week and only 13% used public transportation.Conclusion: People with PCD were very careful and did not seem have an increased risk of infection with SARS-COV-2 nor an especially severe disease course.Funding: PCD support groups: UK, Germany, USA, Australia; SNF 320030B_192804FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA917.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).